| Ticker | Status | Jurisdiction | Filing Date | CP Start | CP End | CP Loss | Deadline |
|---|
| Ticker | Case Name | Status | CP Start | CP End | Deadline | Settlement Amt |
|---|
| Ticker | Name | Date | Analyst Firm | Up/Down | Target ($) | Rating Change | Rating Current |
|---|
In the last three months, 9 analysts have published ratings on Nevro (NYSE:NVRO), offering a diverse range of perspectives from bullish to bearish.
The following table provides a quick overview of their recent ratings, highlighting the changing sentiments over the past 30 days and comparing them to the preceding months.
| Bullish | Somewhat Bullish | Indifferent | Somewhat Bearish | Bearish | |
|---|---|---|---|---|---|
| Total Ratings | 0 | 0 | 5 | 2 | 2 |
| Last 30D | 0 | 0 | 1 | 0 | 0 |
| 1M Ago | 0 | 0 | 4 | 2 | 1 |
| 2M Ago | 0 | 0 | 0 | 0 | 0 |
| 3M Ago | 0 | 0 | 0 | 0 | 1 |
Insights from analysts' 12-month price targets are revealed, presenting an average target of $7.69, a high estimate of $10.00, and a low estimate of $5.50. Highlighting a 36.81% decrease, the current average has fallen from the previous average price target of $12.17.
The analysis of recent analyst actions sheds light on the perception of Nevro by financial experts. The following summary presents key analysts, their recent evaluations, and adjustments to ratings and price targets.
| Analyst | Analyst Firm | Action Taken | Rating | Current Price Target | Prior Price Target |
|---|---|---|---|---|---|
| Richard Newitter | Truist Securities | Lowers | Hold | $5.50 | $10.00 |
| Shagun Singh | RBC Capital | Lowers | Sector Perform | $7.00 | $16.00 |
| Mike Polark | Baird | Lowers | Neutral | $8.00 | $11.00 |
| Nathan Treybeck | Wells Fargo | Lowers | Underweight | $5.50 | $13.00 |
| Adam Maeder | Piper Sandler | Lowers | Underweight | $7.00 | $12.00 |
| Richard Newitter | Truist Securities | Lowers | Hold | $10.00 | $11.00 |
| Cecilia Furlong | Morgan Stanley | Lowers | Equal-Weight | $9.00 | $14.00 |
| Joanne Wuensch | Citigroup | Lowers | Sell | $8.20 | $9.00 |
| Joanne Wuensch | Citigroup | Lowers | Sell | $9.00 | $13.50 |
Assessing these analyst evaluations alongside crucial financial indicators can provide a comprehensive overview of Nevro's market position. Stay informed and make well-judged decisions with the assistance of our Ratings Table.
Stay up to date on Nevro analyst ratings.
If you are interested in following small-cap stock news and performance you can start by tracking it here.
Nevro Corp is a medical device company. Its key product is the HFX spinal cord stimulation (SCS) platform, which includes the Senza SCS system, an evidence-based neuromodulation system for the treatment of chronic pain. Senza generates electrical impulses to relieve pain. The system is implanted by physicians and controlled by patients. It consists of leads, a trial stimulator, an implantable pulse generator, surgical tools, a clinician laptop programmer, a patient remote control, and a mobile charger. The company generates the majority of its revenue in the United States.
Market Capitalization: Indicating a reduced size compared to industry averages, the company's market capitalization poses unique challenges.
Negative Revenue Trend: Examining Nevro's financials over 3 months reveals challenges. As of 30 June, 2024, the company experienced a decline of approximately -4.27% in revenue growth, reflecting a decrease in top-line earnings. When compared to others in the Health Care sector, the company faces challenges, achieving a growth rate lower than the average among peers.
Net Margin: Nevro's net margin excels beyond industry benchmarks, reaching -18.79%. This signifies efficient cost management and strong financial health.
Return on Equity (ROE): The company's ROE is a standout performer, exceeding industry averages. With an impressive ROE of -7.08%, the company showcases effective utilization of equity capital.
Return on Assets (ROA): Nevro's ROA surpasses industry standards, highlighting the company's exceptional financial performance. With an impressive -3.26% ROA, the company effectively utilizes its assets for optimal returns.
Debt Management: Nevro's debt-to-equity ratio is below industry norms, indicating a sound financial structure with a ratio of 0.88.
Analysts work in banking and financial systems and typically specialize in reporting for stocks or defined sectors. Analysts may attend company conference calls and meetings, research company financial statements, and communicate with insiders to publish "analyst ratings" for stocks. Analysts typically rate each stock once per quarter.
Analysts may supplement their ratings with predictions for metrics like growth estimates, earnings, and revenue, offering investors a more comprehensive outlook. However, investors should be mindful that analysts, like any human, can have subjective perspectives influencing their forecasts.
This article was generated by Benzinga's automated content engine and reviewed by an editor.
Posted In: NVRO
